Results 81 to 90 of about 70,411 (245)

Imaging of Abdominal Complications in Children With Acute Lymphoblastic Leukaemia

Journal of Medical Imaging and Radiation Oncology, EarlyView.
ABSTRACT Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy and remains one of the most common causes of cancer‐related death in children and adolescents. Five‐year overall survival rates now exceed 90% with current multidrug chemotherapeutic regimens. This improvement, coupled with the toxicity of chemotherapy, has led to the
Luke R. Holmes, Rishi S. Kotecha, Derek J. Roebuck   +2 more
wiley   +1 more source

ACVIM consensus statement on the treatment of immune thrombocytopenia in dogs and cats

Journal of Veterinary Internal Medicine
Management of immune thrombocytopenia (ITP) in dogs and cats is evolving, but there are no evidence‐based guidelines to assist clinicians with treatment decisions.
Dana N. LeVine, Robert Goggs, Barbara Kohn, Andrew J. Mackin, Linda Kidd, Oliver A. Garden, Marjory B. Brooks, Erin R. B. Eldermire, Anthony Abrams‐Ogg, Elizabeth H. Appleman, Todd M. Archer, Domenico Bianco, Shauna L. Blois, Benjamin M. Brainard, Mary Beth Callan, Claire L. Fellman, Jillian M. Haines, Anne S. Hale, Alice A. Huang, John M. Lucy, Shana K. O'Marra, Elizabeth A. Rozanski, John M. Thomason, Jenny E. Walton, Helen E. Wilson   +24 more
doaj   +1 more source

Family history of haematological malignancy and prognosis across non‐Hodgkin lymphoma subtypes

British Journal of Haematology, EarlyView.
Multivariable‐adjusted associations between family history of haematological malignancy (FHHM) and survival outcomes by non‐Hodgkin lymphoma subtype [OS (A), EFS (B), LSS (C) and failure to achieve EFS at 24 months (D)]. Subtype‐specific analyses showed that FHHM was associated with significantly inferior EFS in MCL and inferior LSS in FL.
George A. Cholack, Raphael Mwangi, Prokop Vodička, Thomas M. Habermann, Verena Hinder, Dennis P. Robinson, Andrew L. Feldman, Thomas E. Witzig, Jose C. Villasboas, Stephen M. Ansell, Brian K. Link, Yucai Wang, Carrie A. Thompson, Susan L. Slager, Matthew Maurer, Anne J. Novak, James R. Cerhan   +16 more
wiley   +1 more source

Lactoferrin- and RGD-comodified, temozolomide and vincristine-coloaded nanostructured lipid carriers for gliomatosis cerebri combination therapy

International Journal of Nanomedicine, 2018
Jicai Zhang, Xiang Xiao, Jianming Zhu, Ziyun Gao, Xianliang Lai, Xingen Zhu, Guohua Mao Department of Neurosurgery, Second Affiliated Hospital, Nanchang University, Nanchang, Jiangxi, China Purpose: Glioblastoma multiforme (GBM) is the most common ...
Zhang J, Xiao X, Zhu J, Gao Z, Lai X, Zhu X, Mao G   +6 more
doaj  

Rapidly Progressive Cutaneous Nodules in an Elderly Woman

JEADV Clinical Practice, EarlyView.
Valeria Olvera‐Rodriguez, Gerardo González‐Martínez, Marion Carolina Alemán‐Jiménez, Minerva Gómez‐Flores, Jorge Ocampo‐Candiani, Lucía T. Fernández   +5 more
wiley   +1 more source

Immunoprofiling, sex‐ and age‐related determinants of treatment response in paediatric, adolescent and young adult Hodgkin lymphoma

British Journal of Haematology, EarlyView.
Multimodal integration of sex‐ and age‐related immune‐gene signatures with baseline tumor burden (TMTV1) improves prediction of treatment response in adolescents and young adults with classical Hodgkin lymphoma. Summary The study investigates how sex and age influence treatment response in paediatric, adolescent and young adult (AYA) classical Hodgkin ...
Valli De Re, Egesta Lopci, Giulia Brisotto, Caterina Elia, Angelo Vitullo, Veronica Paduano, Mariangela De Zorzi, Lara Mussolin, Paola Quarello, Simona Bianchi, Salvatore Buffardi, Alberto Garaventa, Paola Muggeo, Marta Pillon, Alessandra Sala, Luciana Vinti, Emanuele d'Amore, Christine Mauz‐Korholz, Maurizio Mascarin, on behalf of the AIEOP Hodgkin's Lymphoma Study Group, Alberto Garaventa, Alessandra Sala, Antonella Sau, Assunta Tornesello, Daniela Galimberti, Domenico Sperlì, Elena Facchini, Eulalia Galea, Federico Verzegnassi, Fiorina Giona, Francesca Rossi, Fulvio Porta, Irene D’Alba, Katia Perruccio, Luciana Vinti, Marco Zecca, Marta Pillon, Massimo Provenzi, Maurizio Bianchi, Maurizio Mascarin, Monica Cellini, Nadia Vacca, Paola Muggeo, Patrizia Bertolini, Piero Farruggia, Raffaella De Santis, Roberta Pericoli, Rosamaria Mura, Salvatore Buffardi, Salvatore D’Amico, Sayla Bernasconi, Simona Rinieri, Simone Cesaro, Tommaso Casini, Valerio Cecinati   +54 more
wiley   +1 more source

Effects of vincristine on the properties of low threshold mechanoreceptors and high threshold mechanoreceptors in the hindpaw glabrous skin of mice

Molecular Brain
Vincristine is an important chemotherapy drug to treat various types of cancer, but it induces peripheral neuropathy, leading to numbness and mechanical allodynia in the hands and feet of patients. The peripheral neuropathy is a dose-limiting toxicity of
Akihiro Yamada, Ayaka I. Yamada, Jennifer Ling, Jianguo G. Gu   +3 more
doaj   +1 more source

PDH Inhibition in Drosophila Ameliorates Sensory Dysfunction Induced by Vincristine Treatment in the Chemotherapy-Induced Peripheral Neuropathy Models

Biomedicines
Background/Objectives: Chemotherapy-induced peripheral neuropathy (CIPN) is a significant dose-limiting side effect of many effective anticancer agents, including vincristine. While CIPN adversely affects both oncological outcomes and the quality of life
Harim Song, Sohee Kim, Ji Eun Han, Kyong-hwa Kang, Hyongjong Koh   +4 more
doaj   +1 more source

Chemotherapy‐driven expression of WNT ligands in bone marrow stromal cells contributes to chemoresistance in acute lymphoblastic leukaemia

British Journal of Haematology, EarlyView.
Chemotherapy‐induced WNT ligand secretion by bone marrow (BM) stroma drives acute lymphoblastic leukaemia (ALL) chemoresistance. WNT pathway inhibition disrupts this cross‐talk and restores therapeutic response, highlighting WNT inhibitors as a promising strategy to prevent relapse in ALL.
Foteini Kalampalika, Amanda Jiménez‐Pompa, Raúl Sánchez‐Lanzas, Bela Patel, Miguel Ganuza   +4 more
wiley   +1 more source

Functional high‐risk phenotype predicts poor survival in multiple myeloma independent of front‐line treatment: A secondary analysis of CIBMTR data

British Journal of Haematology, EarlyView.
Summary Functional high‐risk (FHR) multiple myeloma (FHRMM) is often defined as progression within 12–24 months of front‐line autologous hematopoietic stem cell transplantation (AHSCT). For patients with early progression after suboptimal front‐line therapies, it is challenging to assign the disease progression to a true FHR phenotype versus less ...
Utkarsh Goel, Catalin Dragomirescu, Saurabh Zanwar, Rafaella Cassano Cassano, Kara I. Cicero, Andrew J. Cowan, Rahul Banerjee, Faiz Anwer, Jack Khouri, Danai Dima   +9 more
wiley   +1 more source